Skip to main content

Lund University Publications

LUND UNIVERSITY LIBRARIES

Serum prostate specific antigen complexed to alpha 1-antichymotrypsin as an indicator of prostate cancer

Christensson, A ; Björk, Thomas LU ; Nilsson, O ; Dahlen, U ; Matikainen, M T ; Cockett, A T ; Abrahamsson, P A and Lilja, Hans LU orcid (1993) In Journal of Urology 150(1). p.100-105
Abstract
Prostate specific antigen (PSA) in serum has recently been shown to occur in complex with alpha 1-antichymotrypsin and as an approximately 30 kDa. noncomplexed molecular form. We characterized PSA by 3 different assays in samples from 144 patients with benign prostatic hyperplasia (BPH) and 121 with carcinoma of the prostate. One of these noncompetitive assays measured total PSA by detecting PSA complexed to serine proteinase inhibitors and the noncomplexed molecular form, a second measured only PSA in complex with alpha 1-antichymotrypsin, whereas a third detected the noncomplexed form. PSA in complex with alpha 1-antichymotrypsin was the predominant form in all patient sera. Noncomplexed PSA constituted a minor fraction that was... (More)
Prostate specific antigen (PSA) in serum has recently been shown to occur in complex with alpha 1-antichymotrypsin and as an approximately 30 kDa. noncomplexed molecular form. We characterized PSA by 3 different assays in samples from 144 patients with benign prostatic hyperplasia (BPH) and 121 with carcinoma of the prostate. One of these noncompetitive assays measured total PSA by detecting PSA complexed to serine proteinase inhibitors and the noncomplexed molecular form, a second measured only PSA in complex with alpha 1-antichymotrypsin, whereas a third detected the noncomplexed form. PSA in complex with alpha 1-antichymotrypsin was the predominant form in all patient sera. Noncomplexed PSA constituted a minor fraction that was significantly smaller in patients with untreated prostate cancer than in those with BPH (p < 0.0001). The proportion of noncomplexed PSA does not correlate to the serum concentration of PSA or that of alpha 1-antichymotrypsin. In men with a serum PSA concentration of less than 10 micrograms./l. the combination of assays measuring total PSA immunoreactivity, the noncomplexed molecular form and PSA in complex with alpha 1-antichymotrypsin may facilitate discrimination between prostate cancer and BPH. (Less)
Please use this url to cite or link to this publication:
author
; ; ; ; ; ; and
organization
publishing date
type
Contribution to journal
publication status
published
subject
in
Journal of Urology
volume
150
issue
1
pages
100 - 105
publisher
Lippincott Williams & Wilkins
external identifiers
  • pmid:7685416
  • scopus:0027243748
ISSN
1527-3792
language
English
LU publication?
yes
id
6b2ade44-cfb6-43c5-b9a4-2a54c57dee20 (old id 1107105)
date added to LUP
2016-04-01 17:04:34
date last changed
2021-10-03 04:13:09
@article{6b2ade44-cfb6-43c5-b9a4-2a54c57dee20,
  abstract     = {{Prostate specific antigen (PSA) in serum has recently been shown to occur in complex with alpha 1-antichymotrypsin and as an approximately 30 kDa. noncomplexed molecular form. We characterized PSA by 3 different assays in samples from 144 patients with benign prostatic hyperplasia (BPH) and 121 with carcinoma of the prostate. One of these noncompetitive assays measured total PSA by detecting PSA complexed to serine proteinase inhibitors and the noncomplexed molecular form, a second measured only PSA in complex with alpha 1-antichymotrypsin, whereas a third detected the noncomplexed form. PSA in complex with alpha 1-antichymotrypsin was the predominant form in all patient sera. Noncomplexed PSA constituted a minor fraction that was significantly smaller in patients with untreated prostate cancer than in those with BPH (p &lt; 0.0001). The proportion of noncomplexed PSA does not correlate to the serum concentration of PSA or that of alpha 1-antichymotrypsin. In men with a serum PSA concentration of less than 10 micrograms./l. the combination of assays measuring total PSA immunoreactivity, the noncomplexed molecular form and PSA in complex with alpha 1-antichymotrypsin may facilitate discrimination between prostate cancer and BPH.}},
  author       = {{Christensson, A and Björk, Thomas and Nilsson, O and Dahlen, U and Matikainen, M T and Cockett, A T and Abrahamsson, P A and Lilja, Hans}},
  issn         = {{1527-3792}},
  language     = {{eng}},
  number       = {{1}},
  pages        = {{100--105}},
  publisher    = {{Lippincott Williams & Wilkins}},
  series       = {{Journal of Urology}},
  title        = {{Serum prostate specific antigen complexed to alpha 1-antichymotrypsin as an indicator of prostate cancer}},
  volume       = {{150}},
  year         = {{1993}},
}